Drug Type Small molecule drug, Liposomal Drug |
Synonyms Liposomal formulation of alpha-D pentaglutamated pemetrexed-D(L.E.A.F. Pharmaceuticals), LEAF 1703, LEAF1703 |
Target |
Action inhibitors |
Mechanism TYMS inhibitors(Thymidylate synthase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 2 | United States | 01 Nov 2024 | |
Non-Small Cell Lung Cancer | Phase 2 | United States | 01 Nov 2024 | |
Ovarian Cancer | Phase 2 | United States | 01 Nov 2024 |